Acute Myeloid Leukemia (AML)

Key Points Ziftomenib shows pronounced preclinical activity in the menin-KMT2A–dependent leukemia models, including patient-derived xenografts. Ziftomenib demonstrates potent activity against a subset of the drug-induced MEN1 mutations found in patients with acute myeloid…

Key Points MLL3 and MLL4 act redundantly in HSCs to sustain transcription factor and enhancer networks that support multipotency. Simultaneous loss of MLL3 and MLL4 drives hematopoietic progenitors into a uniform B-cell–like default state. Abstract Hematopoietic stem cells (HSCs)…

ABSTRACT Introduction Central venous catheter (CVC) insertion is frequently required in patients with haematological diseases. Despite limited evidence, thrombocytopenia often prompts prophylactic platelet transfusion before catheterisation. Methods We conducted an observational…

Abstract Purpose The Children's Oncology Group phase III clinical trial AAML1831 (ClinicalTrials.gov identifier: NCT04293562) evaluated liposomal daunorubicin and cytarabine (CPX-351) versus standard daunorubicin/cytarabine (DA) induction therapy in children and young adults with…

Abstract POEMS syndrome is a rare multisystem plasma cell disorder for which evidence guiding management is largely derived from single-center retrospective series. We conducted a retrospective multicenter study including all consecutive patients diagnosed between January 1995…

Introduction Payers employ health care utilization–management strategies, including prior authorization (PA), to limit costs and promote evidence-based, guideline-concordant care. However, PA may be inconsistently applied and associated with patient confusion and frustration.1-3…

Key Points HMA-VEN is well tolerated in patients with AML/MDS who relapsed after alloHCT. HMA-VEN is effective for relapsed AML/MDS after alloHCT, even in patients who have failed prior VEN-based regimens. Abstract Relapse after allogeneic hematopoietic cell transplantation…

Highlights -Considerable heterogeneity exists in germline testing implementation across hematopoietic stem cell transplantation centers in the United States. -Lack of standardized protocols affects the timing of testing and inconsistent sample collection workflows. -Barriers to…